VTRS INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Viatris Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Core Viewpoint - The Viatris class action lawsuit alleges that the company and its executives misrepresented the impact of regulatory issues on its financial outlook, leading to significant stock price declines following disappointing earnings guidance [3][4]. Group 1: Class Action Lawsuit Details - The class action lawsuit is titled Quinn v. Viatris Inc., and it involves purchasers of Viatris securities from August 8, 2024, to February 26, 2025, with a deadline of June 3, 2025, for lead plaintiff applications [1]. - The lawsuit claims that Viatris downplayed the ramifications of a failed FDA inspection at its Indore facility, which significantly affected its revenue outlook and growth projections [3]. - Following the announcement of disappointing financial results for Q4 and full fiscal year 2024, Viatris' stock price dropped by over 15% on February 27, 2025 [4]. Group 2: Company Background - Viatris is described as a global healthcare company facing challenges related to regulatory compliance and product manufacturing [2]. - The law firm Robbins Geller Rudman & Dowd LLP, which is leading the class action, has a strong track record in securities fraud litigation, having recovered over $2.5 billion for investors in 2024 alone [6].